| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/26/2007 | WO2007046392A1 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 04/26/2007 | WO2007046347A1 Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
| 04/26/2007 | WO2007046112A1 Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| 04/26/2007 | WO2007046111A1 Carbazole derivatives as functional 5-ht6 ligands |
| 04/26/2007 | WO2007045989A1 Pyridyl derivatives useful as h3 ligands |
| 04/26/2007 | WO2007045876A1 Chromenones and their use as modulators of metabotropic glutamate receptors |
| 04/26/2007 | WO2007045672A1 Selected cgrp antagonists method for production and use thereof as medicament |
| 04/26/2007 | WO2007045622A1 Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
| 04/26/2007 | WO2007045620A1 Use of pramipexol for treating moderate to severe restless legs syndrome (rls) |
| 04/26/2007 | WO2007045593A2 Naphthyl derivatives as inhibitors of beta-amyloid aggregation |
| 04/26/2007 | WO2007045478A1 Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders |
| 04/26/2007 | WO2007045432A2 Srf as a diagnostic and/or therapeutic target for diseases that are associated with neuronal abnormalities |
| 04/26/2007 | WO2007045060A1 Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production |
| 04/26/2007 | WO2007028133A3 Treatment and prevention of vascular dementia |
| 04/26/2007 | WO2007024946A3 Methods for the treatment of anxiety and for identification of anxiolytic agents |
| 04/26/2007 | WO2007017145A3 Gsk-3 inhibitors |
| 04/26/2007 | WO2007003675A3 Experimental neuroinflammation model, method of obtaining same and applications thereof |
| 04/26/2007 | WO2006123364A3 Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative |
| 04/26/2007 | WO2006121560A8 Methods and compositions for treatment of cns disorders |
| 04/26/2007 | WO2006117165A3 Means and methods for the treatment of head injuries and stroke |
| 04/26/2007 | WO2006079999A3 Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist |
| 04/26/2007 | WO2006074951A3 Orally disintegrating composition of olanzapine or donepezil |
| 04/26/2007 | WO2006073724A3 Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms) |
| 04/26/2007 | WO2006042724A3 Magnetic particles for therapy and diagnosis |
| 04/26/2007 | WO2006031676A3 Tricyclic anilide spirohydantoin cgrp receptor antagonists |
| 04/26/2007 | WO2005090359A3 Synthesis of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2, 3-b][1,5]benzodiazepine and salts thereof |
| 04/26/2007 | WO2005082883A3 Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| 04/26/2007 | WO2005012304A3 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 04/26/2007 | US20070093530 Substituted indolealkanoic acids |
| 04/26/2007 | US20070093518 Pharmaceutical compositions for the treatment of organophosphate poisoning |
| 04/26/2007 | US20070093510 Phosphodiesterase 4 inhibitors |
| 04/26/2007 | US20070093495 Methods for treatment of parkinson's disease |
| 04/26/2007 | US20070093491 Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases |
| 04/26/2007 | US20070093483 Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) |
| 04/26/2007 | US20070093479 6-chloro-N-(3,3-dimethylbutyl)-5-phenyl-1H-indazol-3-amine; for treating neurodegenerative diseases such as Alzheimer's, fronto-parietal dementia, Pick's disease, Parkinson's disease, type II diabetes, corticobasal degeneration, in which phosphorylation of the tau protein is observed |
| 04/26/2007 | US20070093473 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents |
| 04/26/2007 | US20070093472 1-[(4-Ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors xa and viia for the treatment of thromboses |
| 04/26/2007 | US20070092540 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof |
| 04/26/2007 | US20070092510 Gene expression inhibition; drug screening; reduction of nociception; modulation of the activity and/or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter |
| 04/26/2007 | US20070092504 Use of agents that modulate the interaction between PD-1 and its ligands in the downmodulation of immune responses |
| 04/26/2007 | DE10220149B4 Pharmazeutische Antidepressions-Zusammensetzung, die einen Polygala-Extrakt enthält Anti-depression pharmaceutical composition containing an extract Polygala |
| 04/26/2007 | CA2626249A1 Use of pramipexol for treating moderate to severe restless legs syndrome (rls) |
| 04/26/2007 | CA2626009A1 Selected cgrp antagonists method for production and use thereof as medicament |
| 04/26/2007 | CA2625918A1 Diuretic-like compound analogs useful for regulation of central nervous system disorders |
| 04/26/2007 | CA2625783A1 A1 adenosine receptor agonists |
| 04/26/2007 | CA2625423A1 Cb-1 modulating compounds and their use |
| 04/26/2007 | CA2625341A1 Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
| 04/26/2007 | CA2625204A1 Antioxidant and fe2+ chelating properties of herbal extracts |
| 04/26/2007 | CA2625153A1 Modulation of neurogenesis by pde inhibition |
| 04/26/2007 | CA2624492A1 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 04/26/2007 | CA2622545A1 Naphthyl derivatives as inhibitors of beta-amyloid aggregation |
| 04/26/2007 | CA2622356A1 Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders |
| 04/26/2007 | CA2620248A1 Chromenones and their use as modulators of metabotropic glutamate receptors |
| 04/25/2007 | EP1777236A1 Modified saccharides having improved stability in water |
| 04/25/2007 | EP1777225A1 Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 04/25/2007 | EP1777223A1 Indole derivatives useful as histamine H3 antagonists |
| 04/25/2007 | EP1777222A1 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| 04/25/2007 | EP1777214A2 Novel aryloxy-alkyl-dialkylamines |
| 04/25/2007 | EP1776958A2 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 04/25/2007 | EP1776954A2 The use of inhibitors of the renin-angiotensin system for the treatment of stroke |
| 04/25/2007 | EP1776953A1 Solid oral dosage forms comprising valsartan |
| 04/25/2007 | EP1776950A1 Opioid formulations for treating pain |
| 04/25/2007 | EP1776381A1 Toxin compounds with enhanced membrane translocation characteristics |
| 04/25/2007 | EP1776360A1 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases. |
| 04/25/2007 | EP1776349A2 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace) |
| 04/25/2007 | EP1776344A2 Quinoline derivatives as neurokinin receptor antagonists |
| 04/25/2007 | EP1776343A1 Quinoline derivatives as neurokinin receptor antagonists |
| 04/25/2007 | EP1776337A2 Benzyloxy derivatives as maob inhibitors |
| 04/25/2007 | EP1776160A1 Novel serotonin receptor ligands and their uses thereof |
| 04/25/2007 | EP1776137A1 Pharmaceutical composition containing botulinum neurotoxin a2 |
| 04/25/2007 | EP1776120A1 Novel uses of 2-phenyl-substituted imidazotriazinone derivatives |
| 04/25/2007 | EP1776117A1 Dual nk1/nk3 antagonists against schizophrenia |
| 04/25/2007 | EP1776114A1 Combinations of gaboxadol and 5ht2a antagonists |
| 04/25/2007 | EP1776106A1 Heterocyclic derivatives for modulation of calcium channels |
| 04/25/2007 | EP1776089A2 Donepezil formulations |
| 04/25/2007 | EP1699795B1 Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalklymine]-pyrimido[1,2a]pyrimidin-6-one derivatives |
| 04/25/2007 | EP1697371B1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 04/25/2007 | EP1697370B1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 04/25/2007 | EP1631296B1 2,3,4,5-tetrahydrobenzo¬f|¬1,4|oxazepine-5-carboxylic acid amide derivatives as gamma-secretase inhibitors for the treatment of alzheimer's disease |
| 04/25/2007 | EP1539135B1 Treatment of dyskinesia |
| 04/25/2007 | EP1490401B1 Vegf peptides and their use |
| 04/25/2007 | EP1487834B1 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor |
| 04/25/2007 | EP1408950B1 Methods of treating cytokine mediated diseases |
| 04/25/2007 | EP1401449B1 Tetracyclic compounds as pde5-inhibitors |
| 04/25/2007 | EP1359919B1 Use of quetiapine for the treatment of cocaine dependence |
| 04/25/2007 | EP1326623B1 Saururus chinensis extract for prevention and treatment of neurodegenerative disease |
| 04/25/2007 | EP1315710B1 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 04/25/2007 | EP1309626B1 Cng2b: a putative human cyclic nucleotide-gated ion channel |
| 04/25/2007 | EP1305294B1 Imidazolyl derivatives |
| 04/25/2007 | EP1292326B1 Use of inactive cln2 proenzyme for treating lincl |
| 04/25/2007 | EP1210948B1 Therapeutc peptide for nervous diseases |
| 04/25/2007 | EP1209151B1 4-substituted piperidine derivatives |
| 04/25/2007 | EP1128833B1 Use of agonists of corticosteroid receptors and a drug to treat addiction |
| 04/25/2007 | EP1100780B1 2,3,3a,4,9,9a-HEXAHYDRO-8-HYDROXY-1H-BENZ[F]INDOLES, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS |
| 04/25/2007 | EP1044605B1 Gene mutant animals |
| 04/25/2007 | EP1040101B1 Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments |
| 04/25/2007 | EP0866656B1 Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors |
| 04/25/2007 | CN1953977A Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof |
| 04/25/2007 | CN1953783A Treatment of diseases |
| 04/25/2007 | CN1953760A Herbal formulation containing centella asiatica and sesamum indicum as brain tonic |